Drug
Cenvacibart clinical trials
Also written REGN7508.
- studies test it
- 15
- open now
- 11
- in phase 3
- 8
- first study started
- 2023
Keep track of what changes. Save the cenvacibart studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
- REGN7508
- 14
Studies by the year they started
15 studies that test it; most in 2026 (8)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2024 | 3 |
| 2025 | 3 |
| 2026 | 8 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 3
- Phase 3
- 8
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 15 · Other 0
Often tested with
Tested in the same studies.
Amrecibart (6) · REGN9533 (1)
Studies
Open first, then newest update. How each study uses cenvacibart is read from its arms, and is right about nine times in ten.
Testing it · 15
- REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult ParticipantsRecruitingPhase 3Regeneron PharmaceuticalsNCT07213778Written as REGN7508
- Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic CancersRecruitingPhase 3Regeneron PharmaceuticalsNCT07493304Written as REGN7508
- Safety in Adult Participants With Atrial Fibrillation Who Are Treated With AnticoagulationRecruitingPhase 2Regeneron PharmaceuticalsNCT07175428Written as REGN7508
- Healthy Adult Participants Trial Comparing Different Cenvacibart PresentationsNot yet recruitingPhase 1Regeneron PharmaceuticalsNCT07876505Written as Cenvacibart
- A Study to Evaluate Cenvacibart (REGN7508) for Secondary Stroke Prevention in Adult ParticipantsNot yet recruitingPhase 3Regeneron PharmaceuticalsNCT07876492Written as Cenvacibart
- Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is UnsuitableRecruitingPhase 3Regeneron PharmaceuticalsNCT07430956Written as REGN7508
- REGN7508 in Adult Participants for Prevention of Cancer-Associated ThrombosisRecruitingPhase 3Regeneron PharmaceuticalsNCT07410117Written as REGN7508
- Stroke and Systemic Embolism Prevention in Adult Participants With Atrial FibrillationRecruitingPhase 3Regeneron PharmaceuticalsNCT07626411Written as REGN7508
- REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in AdultsRecruitingPhase 3Regeneron PharmaceuticalsNCT07015905Written as REGN7508
- Study of 3 Monoclonal Antibodies (REGN9933, REGN7508, and REGN9533) in Adult Participants With End-Stage Kidney Disease on HemodialysisRecruitingPhase 1Regeneron PharmaceuticalsNCT07759167Written as REGN7508
- Venous Thromboembolism (VTE) Prophylaxis With REGN7508 and REGN9933 in Adult and Adolescent Participants With a Peripherally Inserted Central Catheter (PICC)RecruitingPhase 3Regeneron PharmaceuticalsNCT07697599Written as REGN7508
- A Trial to Learn How Well REGN7508 Works for Preventing Blood Clots After a Knee Replacement in Adult ParticipantsCompletedPhase 2Regeneron PharmaceuticalsNCT06454630Written as REGN7508
- A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC)CompletedPhase 2Regeneron PharmaceuticalsNCT06299111Written as REGN7508
- Assessment of Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban, or Aspirin Plus REGN9933, or Aspirin Plus REGN7508 in Healthy Adult ParticipantsCompletedPhase 1Regeneron PharmaceuticalsNCT06444178Written as REGN7508
- A Trial to Learn if Single Ascending Intravenous (IV) Doses of REGN7508 Are Safe and Well Tolerated, and How it Works in the Body of Healthy Adult ParticipantsCompletedPhase 1Regeneron PharmaceuticalsNCT05603195Written as REGN7508 (IV)
Given in every arm · 1 — cenvacibart is usual care beside what is tested
Codes
What other systems call cenvacibart · ClinicalTrials.gg INT015301
- UNII (FDA) 6NM5PD4YTHCENVACIBARTOne source FDA
- NCI Thesaurus C214498CenvacibartOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 6NM5PD4YTH | CENVACIBART | One source FDA |
| NCI Thesaurus | C214498 | Cenvacibart | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.